Aridis Pharmaceuticals Probability of Future Pink Sheet Price Finishing Over 0.25
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Aridis |
Aridis Pharmaceuticals Target Price Odds to finish over 0.25
The tendency of Aridis Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 0.25 in 90 days |
| 0.27 | 90 days | 0.25 | about 41.49 |
Based on a normal probability distribution, the odds of Aridis Pharmaceuticals to stay above $ 0.25 in 90 days from now is about 41.49 (This Aridis Pharmaceuticals probability density function shows the probability of Aridis Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Aridis Pharmaceuticals price to stay between $ 0.25 and its current price of $0.27 at the end of the 90-day period is about 15.54 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 3.26 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Aridis Pharmaceuticals will likely underperform. Additionally Aridis Pharmaceuticals has an alpha of 0.8173, implying that it can generate a 0.82 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Aridis Pharmaceuticals Price Density |
| Price |
Predictive Modules for Aridis Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aridis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aridis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aridis Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Aridis Pharmaceuticals is not an exception. The market had few large corrections towards the Aridis Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aridis Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aridis Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.82 | |
β | Beta against Dow Jones | 3.26 | |
σ | Overall volatility | 0.05 | |
Ir | Information ratio | 0.07 |
Aridis Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aridis Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aridis Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aridis Pharmaceuticals is not yet fully synchronised with the market data | |
| Aridis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aridis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.37 M) with loss before overhead, payroll, taxes, and interest of (22.61 M). | |
| Aridis Pharmaceuticals currently holds about 6.32 M in cash with (29.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders |
Aridis Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aridis Pink Sheet often depends not only on the future outlook of the current and potential Aridis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aridis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 4.9 M |
Aridis Pharmaceuticals Technical Analysis
Aridis Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Aridis Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aridis Pharmaceuticals. In general, you should focus on analyzing Aridis Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Aridis Pharmaceuticals Predictive Forecast Models
Aridis Pharmaceuticals' time-series forecasting models is one of many Aridis Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aridis Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Aridis Pharmaceuticals
Checking the ongoing alerts about Aridis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aridis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Aridis Pharmaceuticals is not yet fully synchronised with the market data | |
| Aridis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aridis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.37 M) with loss before overhead, payroll, taxes, and interest of (22.61 M). | |
| Aridis Pharmaceuticals currently holds about 6.32 M in cash with (29.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |